Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as SC VK3019
VK3019 · 1 trial · 1 indication
-Incidence of treatment emergent adverse events (TEAEs) and treatment emergent serious adverse events (TESAEs)
| Arm | Type | Description |
|---|---|---|
| VK3019 Dose Level 1 | EXPERIMENTAL | Single-dose VK3019 or placebo administered subcutaneously |
| VK3019 Dose Level 2 | EXPERIMENTAL | Single-dose VK3019 or placebo administered subcutaneously |
| VK3019 Dose Level 3 | EXPERIMENTAL | Single-dose VK3019 or placebo administered subcutaneously |
| VK3019 Dose Level 4 | EXPERIMENTAL | Single-dose VK3019 or placebo administered subcutaneously |
| VK3019 Dose Level 5 | EXPERIMENTAL | Single-dose VK3019 or placebo administered subcutaneously |
| VK 3019 Dose Level 6 | EXPERIMENTAL | Single-dose VK3019 or placebo administered subcutaneously |
| VK3019 Dose Level 7 | EXPERIMENTAL | Single-dose VK3019 or placebo administered subcutaneously |
| Name | Type | Description |
|---|---|---|
| SC VK3019 | DRUG | Single dose VK3019 |
| Matching placebo | DRUG | Single dose matching placebo |
Inclusion Criteria: * Must be capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the informed consent form (ICF). * Participants must be medically healthy, with no significant medical history, have no clinically significant abnormali...
VK3019 is an investigational small molecule drug being developed by Viking Therapeutics, Inc. for the treatment of obesity in adults. It is in Phase 1 clinical development and is designed to act on the amylin receptor. VK3019 has not been approved by the FDA and remains under clinical study.
VK3019 is being studied for use in overweight and obese adults without comorbidities. The ongoing Phase 1 trial is evaluating the drug in this population. It is an investigational therapy and has not been approved for any indication.
VK3019 targets the amylin receptor, a receptor involved in metabolic regulation. By acting on this receptor, the drug is being developed as a potential treatment for obesity. The amylin receptor is the primary molecular target of VK3019.
VK3019 is being developed by Viking Therapeutics, Inc., a biopharmaceutical company traded on the Nasdaq under the ticker VKTX. Viking Therapeutics is responsible for the clinical development of VK3019.
VK3019 is in Phase 1 clinical development. It is an investigational drug and has not been approved by the FDA. The Phase 1 program is currently ongoing.
VK3019 is being evaluated in a Phase 1 trial, NCT07846033, titled A Phase 1 Study of VK3019 in Overweight and Obese Adults Without Comorbidities. The trial is recruiting and plans to enroll 56 participants in the United States. It is randomized, double-blind, and controlled.
Yes, VK3019 is also known as SC VK3019. Both names refer to the same investigational drug candidate being developed by Viking Therapeutics for obesity. The alternative name SC VK3019 may appear in some references.